- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<
BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting - BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq:
BOSTON --(BUSINESS WIRE)--Feb. 17, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46 th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3,
— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products
BOSTON --(BUSINESS WIRE)--Jan. 20, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
BOSTON --(BUSINESS WIRE)--Jan. 11, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P.
BOSTON --(BUSINESS WIRE)--Dec. 22, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 , at 5:15 p.m.
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients - - Efficacy and safety data in children 5-11 years are consistent with the
<p>BOSTON --(BUSINESS WIRE)--Nov. 19, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner , Chief Operating and Financial Officer, and David Altshuler , Chief Scientific Officer, will participate</p>
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - - Vertex on track to initiate rolling submission of
— Total revenue of $3.08 billion , an 11% increase compared to Q3 2024 — — Refined full year financial guidance: total revenue guidance now $11.9 to $12.0 billion and total combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now $5.0 to $5.1 billion — — R&D pipeline continues to make
BOSTON --(BUSINESS WIRE)--Oct. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference . Reshma Kewalramani , President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11,
- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly in younger people with cystic fibrosis - BOSTON --(BUSINESS WIRE)--Oct.
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous
BOSTON --(BUSINESS WIRE)--Oct. 6, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim analysis data positive - - Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3
- Tatum shares, for the first time, his treatment experience with JOURNAVX while recovering from Achilles injury - BOSTON --(BUSINESS WIRE)--Sep. 23, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson
- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia ( TDT) and sickle cell disease (SCD) in Europe - - Italy has the largest population of people living with TDT in Europe - LONDON --(BUSINESS WIRE)--Sep.
BOSTON --(BUSINESS WIRE)--Sep. 11, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel,
BOSTON --(BUSINESS WIRE)--Aug. 20, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa , Senior Vice President, Investor Relations, and Manisha Pai , Executive Director, Investor Relations, will
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – – Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – BOSTON --(BUSINESS WIRE)--Aug.
— Total revenue of $2.96 billion , a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY ® , ALYFTREK ® and JOURNAVX ® launches — — Rapid advancement of next wave of clinical
- All eligible people with CF in England can now benefit from this medicine - LONDON --(BUSINESS WIRE)--Jul. 14, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine
BOSTON --(BUSINESS WIRE)--Jul. 14, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral,
BOSTON --(BUSINESS WIRE)--Jul. 8, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world - - In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor
- Exclusive collaboration and license agreement for povetacicept in these countries - - Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate advancement of povetacicept for patients with IgA nephropathy
<p>– Results from the study continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit – – All 12 patients with at least one year of follow-up who received a full dose of zimislecel as a single infusion achieved ADA -recommended target HbA1c levels</p>
<p>- Data from longer-term follow-up of patients in clinical trials further demonstrate durability of the transformative benefits of CASGEVY ® - - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world - LONDON - June 12, 2025 - Vertex Pharmaceuticals</p>
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label
BOSTON --(BUSINESS WIRE)--May 15, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa , Senior Vice President, Investor Relations, and Manisha Pai , Executive Director, Investor Relations, will
— Total revenue of $2.77 billion , a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY ® , ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA)
<p>- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene - - In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV 1 and superior compared to KAFTRIO ®</p>
BOSTON --(BUSINESS WIRE)--Apr. 11, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu , Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award “for pioneering research into the cellular and molecular mechanisms
BOSTON --(BUSINESS WIRE)--Apr. 7, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
-Approximately 4,000 people living with CF in the European Union are newly eligible for a medicine that treats the underlying cause of their disease for the first time- LONDON --(BUSINESS WIRE)--Apr. 7, 2025-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit
- Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR modulator therapies - - In head-to-head clinical trials,
-If approved, approximately 4,000 people with cystic fibrosis in the European Union will be eligible for a medicine that treats the underlying cause of their disease for the first time- LONDON --(BUSINESS WIRE)--Feb. 28, 2025-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European
BOSTON --(BUSINESS WIRE)--Feb. 18, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle , Executive Vice President and Chief Operating Officer, and David Altshuler , M.D., Ph.D., Executive Vice
— Full year product revenue of $11.02 billion , a 12% increase compared to full year 2023 — — Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — — ALYFTREK™ approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX™ approved in the U.S.
- Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY - - Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached in August 2024 - LONDON --(BUSINESS WIRE)--Jan. 31, 2025-- Vertex Pharmaceuticals (Nasdaq: VRTX)
<p>-- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- -- JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of</p>
BOSTON --(BUSINESS WIRE)--Jan. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
BOSTON --(BUSINESS WIRE)--Jan. 12, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January
- Exclusive collaboration and licensing agreement for povetacicept in the region - - Zai Lab will leverage its local expertise and commercial footprint to accelerate development of povetacicept and bring the medicine to eligible patients in the region if approved - BOSTON & SHANGHAI & CAMBRIDGE,
BOSTON --(BUSINESS WIRE)--Dec. 23, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m.
- ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared
- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Dec. 20, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.
